Undisclosed 212Pb ART / ARTBIO, 3B Pharma - LARVOL DELTA

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors (PRNewswire) - "ARTBIO, Inc...and 3B Pharmaceuticals GmbH...today announced a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide ART for the treatment of solid tumors. This partnership extends ARTBIO's pipeline with the addition of a highly differentiated program focused on a novel, first-in-class target that is optimal for 212Pb-based alpha radioligand therapy. 212Pb has an ideal clinical profile well suited to this program due to a short half-life and single alpha emission that delivers maximal energy into tumors."

Licensing / partnership • Oncology • Solid Tumor